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cer quickly became known. miRNAs are small non-coding
RNAs that play a vital role in regulation of gene expression.
In the present study, the expression of miR-27b, miR-29a,
and miR-155, their prognostic roles, and their potential targets
in chronic lymphocytic leukemia (CLL) and breast cancer (BC)
by qRT-PCR were investigated. In two case-control studies,
qRT-PCR was used to analyze the peripheral blood serum of
15 CLL patients and tissue samples of 15 BC patients for the
expression of miR-27b, miR-29a, andmiR-155. miRNA expres-
sion levels were calculated using the qRT-PCR method. The
results revealed a significant increase in the expression of all
miRNAs in patients with BC and CLL compared with respec-
tive healthy groups (p < 0.001). In BC patients, there was a
significant difference between the expression of miR-155 and
miR-29a (p < 0.05), miR-155 and miR-27b (p < 0.01), and
miR-27b and miR-29a (p < 0.001). In CLL patients, a signifi-
cant difference between expression of both miR-27b and
miR-29a compared with expression of miR-155 (p < 0.001)
was found. Furthermore, a significant association between
miR-155 and prevascular invasion was found. Significantly,
elevated circulating miRNAs were shown to be BC specific
and could differentiate BC tissues from the controls. It was
demonstrated that miRNAs used in this study and their expres-
sion profiles can be developed as biomarkers for early diagnosis
and prognosis of CLL and BC. Further studies utilizing a larger
test group of patients would provide identification of miRNAs
as key players in intercellular interactions.Received 9 December 2019; accepted 11 January 2020;
https://doi.org/10.1016/j.omto.2020.01.004.
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Chronic lymphocytic leukemia (CLL) is known as one of the most
common leukemias in elderly people and is characterized by the accu-
mulation of mature leukemic B lymphocytes in peripheral blood,
lymphatic organs, and bone marrow. Leukemic cells are resistant to
apoptosis, both spontaneous and induced with anti-leukemic drugs.1230 Molecular Therapy: Oncolytics Vol. 16 March 2020 ª 2020 The Au
This is an open access article under the CC BY license (http://creatiThe heterozygous or homozygous deletion of the chromosomal re-
gion 13q14.3 occurs in more than 50% of CLL cases and is associated
with an indolent clinical course.2 Breast cancer (BC) is the leading
cause of cancer death in women in less-developed countries and the
second most common cause of cancer death in women in developed
countries. With early detection and significant advances in treatment,
death rates from BC have been decreasing in some countries but still
are rising in many countries.3
MicroRNAs (miRNAs) are large subgroups of non-coding RNAs (19–
24 nt), which are evolutionally protected. These molecules control the
expression of a gene after transcription by inhibiting the translocation
ofmRNAor inducing its degradation by connecting the intransitive re-
gion of the end of themiRNAs.4miRNAs can act as a tumor suppressor
by inhibiting the expression of cancer-related target genes and can be
used as a tool to identify and diagnose cancer. The expression of
miRNA is associated with biological and clinical features of the tumor,
such as the tissue type, differentiation, invasion, and response to the
treatment.5 The use of miRNAs as diagnostic markers is possible
through human serumorhumanplasma testing; therefore, it is possible
to detect cancerous miRNAs and tumor cells in serum or plasma non-
invasively.6 miRNAs that are closely associated with malignant pheno-
types can be used as diagnostic markers for a disease in its early stages.
The main mechanism of the epigenetic changes in cancer cells is the
expression of a noncoding gene, which is recognized by the abnormal
levels of adult miRNAs.7 Therefore, cancerous miRNAs can be used
as biological markers for diagnosis, prediction, and treatment.8thors.
vecommons.org/licenses/by/4.0/).
Figure 1. Relative Expression of the miRNAs in
Patient Samples
(A and B) Relative expression of miRNAs in BC cases (A)
and CLL cases (B). ***significant at the 0.001 level. Error
bars show the minimum and maximum variables.
www.moleculartherapy.orgmiRNAs are involved in multiple biological processes, including dif-
ferentiation, proliferation, apoptosis, and stress response through
regulation of gene expression. Up to 30% of human genes are regu-
lated by these small non-coding RNAs. miRNAs are largely conserved
between species and in blood or tissue samples; they are more resis-
tant to degradation than mRNAs. More than 1,000 miRNAs are
known in human at present.9 These molecules are responsible for
the regulation of various physiological processes, and alterations in
their expression levels can reflect different pathological conditions.
Moreover, miRNAs are stable and can be quantified using different
molecular techniques,10,11 such as qRT-PCR.12
Cancer is often heterogeneous in both its clinical course of the patient
and its presentation. In the 1990s, based on RNA extracted from a
fresh tumor tissue, gene expression profiles (GEPs) were introduced
to segregate or classify tumors with similar phenotypes or morphol-
ogies. Because several thousand genes are involved in oncogenic
transformation, these profiles have helped in recognition of pathways
involved in oncogenic transformation. However, only a few selected
cases have been helpful in clinical diagnosis. The discovery of miR-
NAs has made a major impact on cell biology recently.2 Recently,
miRNAs have been recognized as factors that affect the clinical course
of the CLL and may contribute to the leukemogenesis.13,14 Historical-
ly, CLL is reported as the first among human cancers discovered to
clearly associate with alterations of miRNAs expression.1
Some miRNAs, including miR-27b, miR-29a, and miR-155, play
important roles in different types of cancer. Tests based on miRNAs
may improve the classification of BC and the prediction of treatment
responses. Thus far, nomiRNA profile has been tested in larger patient
groups or randomized studies. In 2005, the first comprehensive studyMolecularof miRNA profiles of BC was published.15 The
authors showed that miRNAs were expressed
aberrantly in BC. They could clearly discrimi-
nate the normal breast tissue from the BC tissueusing miRNA profiles. Some of the dysregulated miRNAs correlated
with bio-pathological features, such as progesterone-receptor and
estrogen-receptor expression, vascular invasion, proliferation, and
tumor stage.2 Therefore, according to recent studies, miRNAs in
BC are important for transmitting epithelial mesenchymal and chem-
ical resistance, and could provide potential insights into medical
treatments.16
We hypothesized that expression signatures of the miR-27b, miR-29a,
and miR-155 miRNAs may be useful biomarkers for diagnosis, prog-
nosis, or prediction of CLL and BC. The miRNA expression levels
were evaluated by qRT-PCR.
RESULTS
Expression of three miRNAs (miR-155, miR-29a, and miR-27b) was
detectable in CLL and BC patients and not in healthy subjects. Results
showed a significant increase in the expression of all miRNAs in
patients with BC (Figure 1A) and CLL (Figure 1B) compared with
their respective healthy controls (p < 0.001). Among patients with
BC (Figure 2A), there was a significant difference between the expres-
sion of miR-155 and miR-29a (p < 0.05), miR-155 and miR-27b (p%
0.01), and miR-27b and miR-29a (p < 0.001). miR-27b and miR-29a
in patients with CLL (Figure 2B) were significantly different from
miR-155 (p < 0.001). Comparing expression of miRNAs between
BC and CLL patients (Figure 3), we found a significant difference
for all miRNAs (p < 0.001).
Receiver operating characteristic (ROC) analysis found the optimal
cutoff value for the miRNAs to differentiate BC cases from the con-
trols. Moreover, using ROC analysis, the sensitivities of circulating
miR-155, miR-29a, and miR-27b were defined to be 84.4%, 93.3%,Figure 2. Comparison of the Three miRNAs in
Patient Samples
(A and B) Comparison of the three miRNAs in BC (A) and
CLL (B). *significant at the 0.05 level, **significant at the
0.01 level, and ***significant at the 0.001 level. Error bars
show the minimum and maximum variables.
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Figure 3. Comparison of the Three miRNAs in BC with CLL
***significant at the 0.001 level. Error bars show theminimumandmaximum variables.
Molecular Therapy: Oncolyticsand 100% at the specificities of 91.1%, 91.1%, and 100% with an area
under the ROC curve of 0.941, 0.969, and 1, respectively (Figure 4).
In Figure 5, ROC curves for miRNAs showed differentiation of the
CLL cases from the controls. The sensitivities of circulating miR-
155, miR-29a, and miR-27b were 100%, 91.1%, and 100% at the spec-
ificities of 100%, 100%, and 100% with an area under the ROC curve
of 1, 0.995, and 1, respectively.
Correlations between the Expression of the miRNAs
Table 1 shows the correlations between miRNAs expression. There
were no significant correlations between the miRNAs expression
(p > 0.05).
Correlations between miRNAs Expression and Clinical
Parameters
Table 2 shows the correlations between miR-155 expression and clin-
ical variables (age, tumor grade, nuclear grade, tumor stage, tumor
size, area of invasive component, tumor side, margin, prevascular
invasion, and preneural invasion). There was a significant correlation
between miR-155 expression and prevascular invasion (p = 0.013),
whereas no significant correlation between miR-155 expression and
other clinical variables was found. Furthermore, Tables 3 and 4 indi-
cate no significant correlations between miR-27b expression and clin-
ical parameters and also between miR-29a expression and clinical
variables (p > 0.05), respectively.Figure 4. Receiver Operating Characteristic (ROC) Curve Analyses of the Thre
Controls
232 Molecular Therapy: Oncolytics Vol. 16 March 2020Correlation between miRNAs Expression and Survival in BC
Patients
The log rank test was used in BC patients. We used the Cox propor-
tional hazards regression model also to evaluate the predictive value
of miRNAs levels in BC patients. The time between the date of surgery
and date of death or last follow-up was defined as overall survival
(OS). Clinicopathological factors and OS were then analyzed in the
high- and low-miRNA expression groups, but no significant differ-
ences were found between groups (p > 0.05; Table 5; Figure 6).DISCUSSION
In this study, we examined the expression profile of three miRNAs
(miR-27b, miR-29a, and miR-155) in CLL and BC. The results
revealed that miR-27b, miR-29a, and miR-155 were significantly up-
regulated in BC as compared with non-tumor tissues. On the other
hand, miR-155 expression was also significantly increased in CLL pa-
tients compared with healthy ones, but miR-27b and miR-29a levels
were downregulated in CLL.
miRNAs play a variety of roles in cancer initiation, tumor growth, and
metastasis. Also, miRNAs may be valuable biomarkers for cancer
diagnosis and therapy.17 The comparative study by Moussay et al.14
has shown that the expression of most circulating miRNAs in CLL pa-
tients reflects their expression in leukemic cells like in solid tumors.
The level of miRNA expression in CLL, however, is decreased as
compared with miRNA expression assessed in leukemic lympho-
cytes.18 miRNAs, such as miR-34a-5p, miR-31-5p, miR-155-5p,
miR-15a-3p, and miR-29a-3p, were expressed at the highest level in
CLL patients.1 In several studies, miRNA expression was shown to
differentiate between CLL patients and healthy individuals, and
they all have been corroborated as important for the CLL develop-
ment and the clinical course of the disease.19–22 In another study, Li
et al.23 reported overexpression of miR-34a and miR-155 in CLL lym-
phocytes and defined it as a part of activated B cell phenotype. miR-
155 expression in B lymphocytes was found to differentiate between
normal individuals, individuals with CLL, and monoclonal B cell
lymphocytosis (MBL); its overexpression in the latter group was asso-
ciated with aggressive disease.24 Ferrajoli et al.25 demonstrated the
presence of miR-155 in circulating micro-vesicles of individuals
with CLL and MBL. A combination of nine miRNAs (expressione miRNA Signature to Discriminate Breast Cancer Patients from Normal
Figure 5. ROC Curve Analyses of the Three miRNA Signature to Discriminate CLL Patients from Normal Controls
www.moleculartherapy.orgprofile miR-181 up, miR-155 up, miR-146 up, miR-24-2 up, miR-23b
up, miR-23a up, miR-222 up, miR-221 up, and miR-29c down) corre-
lated with a short interval to progression. In the same study, the germ-
line or somatic mutations of some miRNA genes were found in 11 of
75 patients with CLL. This finding showed a genetic disposition for
cancer in some patients with CLL.2
Several recent studies have demonstrated that the expression of miR-
27a is upregulated in several types of solid tumors, including colon,
gastric, cervical, and BCs.26 The widespread overexpression of miR-
27a in cancer has led to the belief that miR-27a is an oncogenic
miRNA.27 In the present study, miR-27a was upregulated in patients
with metastases, suggesting that its upregulation was acquired in the
course of tumor progression and during the acquisition of metastatic
potential. Several studies have revealed the prognostic significance of
miR-27a overexpression in various carcinomas, such as gastric can-
cer,28 acute lymphoblastic leukemia,29 and osteosarcoma.30 Tang
et al.31 indicated that breast-invasive cancers with higher miR-27a
expression tended to have distant metastasis, and the overexpression
of miR-27a was associated with shorter disease-free survival and OS
of BC patients. Both the univariate analyses and multivariate ana-Table 1. Correlation between miRNAs Expression
miR-155 miR-27b miR-29a
Gene Low High Low High Low High
miR-155
Low 33.3 13.3 20 26.7
High 13.3 40 26.7 26.7
p value 0.072 0.782
miR-27b
Low 33.3 13.3 13.3 33.3
High 13.3 40 33.3 20
p value 0.072 0.189
miR-29a
Low 20 26.7 13.3 33.3
High 26.7 26.7 33.3 20
p value 0.782 0.189lyses indicated that miR-27a expression was an independent prog-
nostic factor for BC progression.27 Anti-apoptosis functions of
miR-29a in BC cells have been reported by Choghaei et al.32 These
controversial results of miR-29a in tumors indicated that based on
the cancer type, miR-29a played different roles. In our study, we
found that miR-29a was significantly upregulated in BC as compared
with normal tissues, indicating that miR-29a was implicated in the
progression of BC.33
miR-155, involved in the progression of lymphoma,34 has more than
400 predicted gene targets, including over 100 confirmed ones.
miR-155 is an oncogenic miRNA that has been explored mainly in
leukemia but is also known to play an important role in the progres-
sion of BC.35 Several studies suggest that the miR-155 expression is
upregulated in BC. miR-155 overexpression is associated with high
mortality and tumor subtype.36 Iorio et al.15 indicated that out of
29 different miRNAs that were downregulated, just miR-155 was
significantly upregulated in BC, and introduced miR-155 as an
important player in BC. In another study, serum miR-155 was also
significantly increased in BC patients compared with healthy do-
nors.37 Another study indicated overexpression of miR-155 in BC
and suggested its potential clinical prognostic value.36 Upregulation
of miR-155 in BC has been shown to be significantly associated with
advanced tumor stage, higher tumor grade, and lymph node metas-
tasis, suggesting its potential as a clinical prognostic marker.38 As a
limitation of our study, small sample size could be mentioned, which
may reduce the accuracy of the results.
In conclusion, our results suggest that miR-27b, miR-29a, and
miR-155 could be potential new biomarkers for diagnosis, as well
as a therapeutic target for CLL and BC. Future studies including a
large group of multi-ethnic patients are required to validate our
findings.MATERIALS AND METHODS
Patients and Healthy Controls
A total of 15 CLL and 15 BC patients admitted to the Isfahan General
Hospital were selected for the study. The study protocol included a
standard oncological evaluation with subsequent review of histopath-
ological data and outpatient follow-ups. Blood samples were collected
from the CLL patients and tumor tissue samples from the BC patients.Molecular Therapy: Oncolytics Vol. 16 March 2020 233




Age, 46.80 ± 2.57 0.782
%47 years 53.3 26.7 26.7
>47 years 46.7 20 26.7
Tumor Grade 0.170
I 6.7 6.7 0
II 66.7 20 46.7
III 26.7 20 6.7
Nuclear Grade 0.223
Low 7.1 7.1 0
High and intermediate 28.6 21.4 7.1
High 64.3 21.4 42.9
Tumor Stage 0.098
T1 40 33.3 6.7
T2 13.3 0 13.3
T3 40 13.3 26.7
T4 6.7 0 6.7
Tumor Size (cm) 0.185
% 2 73.3 26.7 46.7
> 2 26.7 20 6.7
Area of Invasive Component, 4.09 ± 0.13 cm2 0.143
%4 66.7 40 6.7
>4 33.3 26.7 26.7
Tumor Side 0.438
Right 53.3 26.7 26.7
Left 46.7 20 26.7
Margin 0.876
Free 73.3 33.3 40
Involved 26.7 13.3 13.3
Prevascular Invasion 0.013*
Negative 26.7 26.7 0
Positive 73.3 20 53.3
Preneural Invasion 0.438
Negative 20 13.3 6.7
Positive 80 33.3 46.7
*p < 0.05.




Age, 46.80 ± 2.57 0.189
%47 years 53.3 33.3 20
>47 years 46.7 13.3 33.3
Tumor Grade 0.626
I 6.7 0 6.7
II 66.7 33.3 33.3
III 26.7 13.3 13.3
Nuclear Grade 0.05
Low 7.1 0 7.1
High and intermediate 28.6 28.6 0
High 64.3 21.4 42.9
Tumor Stage 0.400
T1 40 20 20
T2 13.3 0 13.3
T3 40 20 20
T4 6.7 6.7 0
Tumor Size (cm) 0.185
%2 73.3 26.7 46.7
>2 26.7 20 6.7
Area of Invasive Component, 4.09 ± 0.13 cm2 0.464
%4 66.7 26.7 40
>4 33.3 20 13.3
Tumor Side 0.782
Right 53.3 26.7 26.7
Left 46.7 20 26.7
Margin 0.876
Free 73.3 33.3 40
Involved 26.7 13.3 13.3
Prevascular Invasion 0.876
Negative 26.7 13.3 13.3
Positive 73.3 33.3 40
Preneural Invasion 0.243
Negative 20 6.7 13.3
Positive 80 40 40
Molecular Therapy: OncolyticsHealthy controls (n = 15) were recruited and were matched to the pa-
tients by age and gender. Informed consents were obtained. The time
between the date of surgery and date of death or last follow-up was
defined as OS.
PBMCs Isolation
Peripheral blood mononuclear cells (PBMCs) were separated by
density gradient lymphosep (Bio Sera, Kansas City, USA) accord-234 Molecular Therapy: Oncolytics Vol. 16 March 2020ing to the manufacturer’s instructions. 4 mL of blood was diluted
at a ratio of 1:1 with physiological saline and gradually added to
the 4 mL Lymphoprep solution gradient in a Falcon tube and
was centrifuged at 800  g for 30 min at room temperature.
Then, PBMCs were transferred from the middle phase into a
2-mL RNase-free micro tube. After washing and cell counting,
PBMCs were sedimented using centrifugation for 10 min at
250  g and were then frozen at 70C until the RNA extraction
stage.




Age, 46.80 ± 2.57 0.447
%47 years 53.3 20 33.3
>47 years 46.7 26.7 20
Tumor Grade 0.512
I 6.7 6.7 0
II 66.7 26.7 40
III 26.7 13.3 13.3
Nuclear Grade 0.348
Low 7.1 7.1 0
High and intermediate 28.6 7.1 21.4
High 64.3 35.7 28.6
Tumor Stage 0.517
T1 40 26.7 13.3
T2 13.3 6.7 6.7
T3 40 13.3 26.7
T4 6.7 0 6.7
Tumor Size (cm) 0.185
%2 73.3 26.7 40.7
>2 26.7 20 6.7
Area of Invasive Component, 4.09 ± 0.13 cm2 0.143
%4 66.7 40 26.7
>4 33.3 6.7 26.7
Tumor Side 0.782
Right 53.3 26.7 26.7
Left 46.7 20 26.7
Margin 0.185
Free 73.3 26.7 46.7
Involved 26.7 20 6.7
Prevascular Invasion 0.310
Negative 26.7 6.7 20
Positive 73.3 40 33.3
Preneural Invasion 0.605
Negative 20 6.7 13.3
Positive 80 40 40
Table 5. Log Rank Test for All Patients Undergoing Breast Cancer
Variables Overall Survival
HR 95% CI p Value
miR-155 (low versus high) 1.681 0.3333–8.280 0.540
miR-27b (low versus high) 1.215 0.2458–6.126 0.807
miR-29a (low versus high) 2.484 0.5871–15.15 0.197
Age (%47 versus >47 years) 1.749 0.3501–8.657 0.506
Tumor grade (I-II versus III) 0.560 0.07296–3.501 0.493
Nuclear grade (low versus high and
intermediate-high)
1.977 0.1596–40.67 0.517
Tumor stage (T1-T2 versus T3-T4) 0.5445 0.1041–2.891 0.800
Tumor size (<2 versusR2 cm) 0.460 0.04656–2.841 0.347
Area of invasive component
(<4 versusR4 cm2)
0.576 0.07625–3.827 0.378
Tumor side (right versus left) 0.585 0.1185–2.937 0.525
Margin (free versus involved) 0.507 0.05886–3.166 0.416
Prevascular invasion (negative versus
positive)
1.605 0.3264–8.170 0.566
Preneural invasion (negative versus positive) 0.336 0.01890–1.809 0.166
CI, confidence interval; HR, hazard ratio.
www.moleculartherapy.orgRNA Extraction
Total RNA from PBMCs was extracted using miRNA Hybrid-R
(GeneAll, Seoul, Korea) based on the manufacturer’s instructions.
For BC samples, 100 mg tissue per extraction was homogenized in
liquid nitrogen using a pestle and a mortar. Total RNA was extracted
from tissue samples using the RNX-Plus solution (SinaClon, Iran)
according to the manufacturer’s instructions. Quality and quantity
of RNA were assessed by means of NanoDrop spectrometer (Thermo
Scientific, Waltham, MA, USA). Samples containing at least 5 ng/mLof RNA, with A260/A280 ratio between 1.7 and 2.1, were used for
further analysis. Isolated RNA was stored at 70C.
cDNA Synthesis and Real-Time PCR
cDNA synthesis of miR-27b, miR-29a, and miR-155 was performed
using a commercial kit (Pars Genome, Tehran, Iran) and according
to the manufacturer’s instructions. Real-time quantitative PCRs
were accomplished in triplicate. In brief, in a total volume of 10 mL,
20 ng/mL cDNA product was added to a master mix, including 10
pmol/mL of miR-27b, miR-29a, and miR-155 U6 (housekeeping)
primers (Pars genome) and 5 mL of SYBR premix ExTaqII (TaKaRa,
Kusatsu, Shiga Prefecture, Japan). The run program was set at 95C
for 5 min followed by 40 cycles of 95C for 5 s, 58C for 20 s, and
72C for 30 s.
Statistical Analysis
Real-time PCR data analysis was performed using the 2DDCt method,
and the final result was normalized by U6 (small nuclear RNA) as an
endogenous control.39 Student’s t test was conducted to compare
miRNAs expression in clinical samples. The ROC curves were used
to estimate the diagnostic value of the identified miRNAs on the
CLL and BC by calculation sensitivity and specificity for each possible
cutoff point of the individual miRNAs. This was performed univari-
ately for each individual miRNA. The patients were divided based on
the median value of the miRNAs expression into two groups: cases
with high miRNAs and cases with low miRNAs expression. The
chi-square test and Fisher’s exact test were applied to evaluate
correlations of miRNAs expressions and clinical parameters. We
investigated the association between the expression levels of miRNAsMolecular Therapy: Oncolytics Vol. 16 March 2020 235
Figure 6. Kaplan-Meier Survival Curves for Associations of miRNAs with Survival
The miRNAs expression and overall survival (OS) in all patients: miRNAs low versus high, p > 0.05 (log rank test).
Molecular Therapy: Oncolyticswith survival through Kaplan-Meier analysis in order to assess the
prognostic value of miRNAs as a biomarker for BC. The log rank
test was used in BC patients data. We also used the Cox proportional
hazards regression model to evaluate the predictive value of miRNAs
levels in BC patients. All statistical tests were performed using REST
2009 and Graph Pad Prism statistical software, version 7.00 (Graph
Pad, San Diego, CA, USA). For all tests, a p value <0.05 was consid-
ered statistically significant.
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